На главную
Результаты поиска “Leuprolide for prostate cancer”
Hormone Therapy Side Effects
 
01:48
Edward Weber, M.D. Medical Oncologist, describes the side effects of cardiac complications when receiving Androgen Deprivation Therapy, ADT, also known as Hormone Therapy, for treatment of Prostate Cancer. ADT is used to reduce the production of testosterone needed for the growth of prostate cancer cells. But ADT can have cardiac complications, especially on men with a history of heart disease. Video Development: Dean Dubinsky Video Transcript: Prostate Cancer Free Foundation. Increasing Knowledge - Building Hope. Edward Weber, M.D. Medical Oncologist, Prostate Cancer Results Study Group. Men with prostate cancer are much more likely to die of cardiac disease and not from prostate cancer, unless the diagnosis is made at a very late stage.  For that reason, a man’s cardiac history, his cardiovascular risk factors, and the choice of which drug to use for ADT are very critical issues. Androgen deprivation therapy, ADT, the  mainstay of treatment for years, is associated with a 10-20% increased risk of cardiac complications, such as a heart attack, stroke, or sudden death. If a man has already had two important cardiac events before starting ADT the risk of another cardiac event is greatly increased. Surprisingly these serious problems can occur within the  first 6 - 12 months. Degarelix (Firmagon), the newer drug for ADT, is less toxic to the heart than leuprolide (Lupron), and, for many clinicians, is becoming the preferred agent for hormone therapy. Every man before starting ADT needs to have a thorough evaluation for cardiac risk factors. This exam should focus on past history of cardiovascular disease, hypertension, diabetes, elevated cholesterol and triglycerides, and the life-style factors diet and exercise habits.   In some men this pre-ADT evaluation will lead to choosing Firmagon over Lupron, or receiving the shortest period of drug exposure as possible, or beginning a program for modification of cardiac risk factors — or possibly avoiding the use of these drugs entirely. Prostate Cancer Free Foundation https://prostatecancerfree.org
Просмотров: 9183 Prostate Cancer Free Foundation
Possible Side Effects of Prostate Cancer Treatment
 
04:39
Treatment options for prostate cancer can lead to a range of side effects. Dr. Arthur Burnett, Patrick C. Walsh Distinguished Professor of Urology, Director, Basic Science Laboratory in Neurourology and Director, Male Consultation Clinic at Johns Hopkins Medical Institutions discusses these possible side effects and how men and their family and caregivers can manage the impact of treatment.
Просмотров: 4340 Genomic Health, Inc.
Prostate Cancer Injections
 
02:05
Newly-approved prostate cancer ejections giving cancer patients more quality of life.
Просмотров: 5582 Denver7 – The Denver Channel
Rahj vs Lupron - My Prostate Cancer Journey
 
05:07
This is simply me sharing my journey about me going through the process of prostate cancer. I'm just trying to spread awareness and knowledge. Hopefully I can help someone who's been going through the same process.
Просмотров: 57 King Rahj
Hormonal Therapy for Prostate Cancer
 
22:00
A discussion of hormonal therapy for prostate cancer patients considering their treatment options
Просмотров: 28793 CancerClinicalTrials
Dr. Slovin on an Ongoing Study With Degarelix Leuprolide in Prostate Cancer
 
00:55
Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.
Просмотров: 79 OncLiveTV
Neoadjuvant abiraterone acetate plus leuprolide acetate for localised high-risk prostate cancer
 
05:04
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa for patients with localised high-risk prostate cancer.
Просмотров: 627 European Medical Group
Dr. Andre Goy on Neoadjuvant Leuprolide and Abiraterone in High Risk Localized Prostate Cancer
 
01:35
Andre Goy, MD, MS, chief, Lymphoma Division, chairman, John Theurer Cancer Center at Hackensack University Medical Center, discusses a phase II trial that combined leuprolide acetate with abiraterone acetate before prostatectomy in patients with localized high-risk prostate cancer. Read more at http://www.onclive.com/onclive-tv/Dr-Goy-on-Neoadjuvant-Hormonal-Therapy-Plus-Zytiga
Просмотров: 435 OncLiveTV
Androgen deprivation therapy for prostate cancer
 
01:19
Today, CancerBro will explain what is prostate cancer deprivation therapy. Video Transcript: The next treatment modality is androgen deprivation therapy. For this, we first have to understand the hormonal axis causing the testosterone release. Pituary gland releases LH and FSH, which directly acts on the testis to release testosterone. ACTH released from pituitary gland acts on the adrenal gland to release DHEA, which subsequently gets converted into testosterone. The testosterone released from testis and adrenal gland enters the prostate cell and gets converted into DHT which causes the growth and survival of prostate cancer cells. We can block this pathway, to reduce the action of testosterone on prostate cancer cells. GNRH agonists or antagonists prevents the release of LH, FSH and ACTH from pituitary gland. Then come the cytochrome 17P inhibitors that prevent the release of testosterone from testis and adrenal gland. And finally there are androgen receptor blockers that prevents the binding of testosterone to prostate cancer cells, thereby preventing it's action. Another method for androgen deprivation is surgical castration in which both testes are removed. Unlike medical constration it is a one time procedure. CancerBro is also active on most social media channels. Follow him to get rich and authoritative content related to cancer awareness, risk factors, symptoms, diagnosis, treatment, etc. Facebook - https://www.facebook.com/officialcancerbro/ Instagram - https://www.instagram.com/official_cancerbro/ Twitter - https://twitter.com/cancer_bro/ Website - http://www.cancerbro.com/
Просмотров: 129 CancerBro
Prostate Cancer Hormone Side Effects
 
01:49
Edward Weber, M.D. Medical Oncologist, describes the side effects of cardiac complications when receiving Androgen Deprivation Therapy, ADT, also known as Hormone Therapy, for treatment of Prostate Cancer. Video Developer: Dean Dubinsky Website: ProstateCancerFree.org Transcript: Prostate Cancer Free Foundation. Increasing Knowledge – Building Hope. Edward Weber, M.D. Medical Oncologist, Prostate Cancer Results Study Group. Men with prostate cancer are much more likely to die of cardiac disease and not from prostate cancer, unless the diagnosis is made at a very late stage. For that reason, a man’s cardiac history, his cardiovascular risk factors, and the choice of which drug to use for ADT are very critical issues. Androgen deprivation therapy, ADT, the mainstay of treatment for years, is associated with a 10-20% increased risk of cardiac complications, such as a heart attack, stroke, or sudden death. If a man has already had two important cardiac events before starting ADT the risk of another cardiac event is greatly increased. Surprisingly these serious problems can occur within the first 6 – 12 months. Degarelix (Firmagon), the newer drug for ADT, is less toxic to the heart than leuprolide (Lupron), and, for many clinicians, is becoming the preferred agent for hormone therapy. Every man before starting ADT needs to have a thorough evaluation for cardiac risk factors. This exam should focus on past history of cardiovascular disease, hypertension, diabetes, elevated cholesterol and triglycerides, and the life-style factors diet and exercise habits. In some men this pre-ADT evaluation will lead to choosing Firmagon over Lupron, or receiving the shortest period of drug exposure as possible, or beginning a program for modification of cardiac risk factors — or possibly avoiding the use of these drugs entirely. Prostate Cancer Free Foundation. www.prostatecancerfree.org
Просмотров: 1485 Prostate Cancer Free Foundation
Androgen Deprivation Therapy for Prostate Cancer and You
 
04:48
Androgen Deprivation Therapy for Prostate Cancer and You
Просмотров: 1072 Lakeridge Health
The Role of Abiraterone in Prostate Cancer
 
02:06
Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses the role of abiraterone acetate (Zytiga) in the treatment of patients with prostate cancer, and the questions that remain about its use.
Просмотров: 726 Targeted Oncology
Can Lupron cure prostate cancer
 
01:58
Can Lupron cure prostate cancer - Find out more explanation for : 'Can Lupron cure prostate cancer' only from this channel. Information Source: google
Просмотров: 12 Arif Hidayat
Surviving Lupron
 
14:45
The things I did to survive, bounce back and fully recover from my Lupron injections following endometriosis surgery. This video specifically discusses JOINT PAIN!!! I'm not claiming that these steps will reverse other immune or hormone disorders.
Просмотров: 2433 Victoria von Rhine
Prostate Cancer Oligometastases | Dr. Kwon | 2014 Prostate Cancer Patient Conference
 
50:09
Prostate Cancer Research Institute 2014 Prostate Cancer Patient Conference Prostate Cancer Oligometastases | Dr. Eugene Kwon
Просмотров: 565 Prostate Cancer Research Institute
McDougall, MD- Prostate Cancer
 
28:31
Best-selling author, John McDougall, MD, brings a wealth of information on common and uncommon conditions, diseases, and injuries. The McDougall Plan is known around the world for its success in weight loss, reversing diabetes, and reducing heart disease.
Просмотров: 138 Smart LifeStyle TV
Prostate Cancer DREX KRISTI FINAL
 
00:31
Просмотров: 133 ProstateCancerBC
How To Prepare Leuprolide Acetate Injection?
 
02:09
Many of doctors or nurses do not know how to prepare Leuprolide acetate injection, so we have filmed this video tutorial so that you can understand it better. The procedure seems to be quite complicated, but it is very simple. But you must take during attaching needle, otherwise material may ooze out due to negative pressure.
Просмотров: 42550 Dr. Vikram
Lupron or Leuprolide Injection Video for IVF
 
03:15
Lupron or Leuprolide is used to overstimulate the production of some hormones in the body, view this video for a full step by step demonstration for getting started on your lupron injections. Learn more about fertility and options for IVF treatments here: http://haveababy.com/infertility-treatments/in-vitro-fertilization-ivf To contact us find the nearest fertility clinic to you with the contact information below, or through our on-site contact form at http://haveababy.com/fertility-clinics Central Illinois Fertility Clinic 5401 N. Knoxville Ave., Suite 102 Peoria, IL 61614 Phone: (309) 689-0411 Dallas Fertility Clinic 7777 Forest Lane, Suite C-638 Dallas, TX 75230 Phone: (972) 566-6686 Las Vegas Fertility Clinic 5320 S. Rainbow Blvd., Suite 300 Las Vegas, NV 89118 Phone: (702) 892-9696 New York Fertility Clinic 425 Fifth Ave., 3rd Floor New York, NY, 10016 Phone: (646) 792-7476 Westchester Fertility Clinic 3020 Westchester Ave., Suite 304 Purchase, NY 10577 Phone: (914) 696-7476 New Jersey Fertility Clinic 171 State Route 173 Asbury, New Jersey 08802 Phone: (908) 781-0666 St. Louis Fertility Clinic 555 N. New Ballas Rd., Suite 150 Creve Coeur, MO 63141 Phone: (314) 983-9000
Просмотров: 23840 Sher Fertility Institute
Benign Prostate Hyperplasia (BPH) and Prostate Cancer for USMLE Step 2
 
34:35
Benign Prostatic Hyperplasia (BPH) and Prostate Cancer epidemiology, etiliogy, causes and symptoms, investigations, treatment and management. Handwritten full lecture for USMLE. ANATOMY of PROSTATE Central zone of prostate sorrounds ejaculatory duct. The Transitional zone of prostate encompases meddle part of urethra. Peripheral zone is placed outside. Prostate cancer is most common in peripheral zone (60-70%). The Central zone is the second most common site for prostate cancer (25%). The Transition zone only has an occurence rate of 5% for prostate cancer. Benign Prostate Hyperplasia (BPH) is in the transition zone and that is why it presents mostly with urinary symptoms. BENIGN PROSTATIC HYPERPLASIA (BPH) Prostate is heavily influenced by DHT and testosterone, however, DHT is ten times more sensitive. Testosterone is converted to DHT by 5alpha reductase. This causes hyperplasia of collagen cells and the smooth muscle. The collagen will cause a physical obstruction while the smooth muscle will cause mechanical obstruction. Eventually there is bladder enlargement which may forma false diverticulum (outpouching of the bladder). Clinical Signs and Symptoms Obstructive symptoms - Consists of the patients experiencing hesitancy, difficulty voiding, straining, decrease in the force of stream and dribbling of urine. Irritation symptoms - increase frequency or urgency as well as nocturia. These symptoms occur as the bladder gets larger and begins to overflow. These symptoms can produce an International Prostate Symptoms Score (IPSS) which determines severity of Benign prostatic Hyperplasia through symptoms. Diagnosis of Benign Prostatic Hyperplasia Digital Rectum Exam is done initially, however it doesn't correlate well with symptoms and it is very difficult to palpate. Urinalysis is also done to rule out prostatitis. PSA is organ specific but can be elevated in cancer and prostatitis. Ultrasound or CT to look for complications such as bladder distention. Transrectal ultrasound is used before surgery. Treatment for Benign Prostatic Hyperplasia (BPH) If the degree of benign prostatic hyperplasia (BPH) is minimal such as 0-7 on the IPSS score than watchful waiting because most spontaneously. So for these patients continue monitoring PSA and Digital Rectums Exams. If getting worse continue to medical treatment. Alpha 1 blocker allows relaxation of the smooth muscle that may be constricting the urethra. Finasteride is a 5 alpha reductase inhibitor to prevent formation of DHT from testosterone and help debulk the prostate. Commonly used drugs are terazosin and doxazosin but this can lead to hypotension. More specific is an Alpha A1 blocker such as tamsolusin which is more specific for the prostate and therefore hypotension is not present but can lead to retrograde ejaculation. Surgery - If medical therapy doesn't work for the Benign Prostatic Hyperplasia (BPH). Two procedures transurethral and prostatectomy. PROSTATE CANCER CLINICAL SIGNS AND SYMPTOMS of PROSTATE CANCER Can range from asymptomatic to completely fatal. Screening - Digital Rectal Exam is not helpful and PSA is the only method being used. Local Disease causes symptoms similar to Benign Prostatic Hyperplasia symptoms, but this suggests involvement of the transition zone. Metastasis disease include symtpoms related to osteoblastic bone growth, primarily the spine leading to neurological symptoms and back pain. Prostatic Cancer patients may also have patients related to lower extremities due to lymphatic obstruction INVESTIGATION for PROSTATE CANCER Digital Rectal Exam shows a single nodule and correlates well with severity of disease. However, it may be a cyst or a stone. PSA normally should be less than 2.5ng/dL (some say less than 4 ng/dL). May also be helpful to measure as PSA Velocity and Free PSA versus Bound PSA. This helps distinguish Benign Prostatic Hyperplasia from Prostate Cancer. Transrectal Ultrasound may also be used. Biopsy uses the Gleasson Score which looks at the tissue of prostate under microscope and given a score out of 5. Staging of prostate cancer utilizes the TNM score. TREATMENT AND MANAGEMENT of PROSTATE CANCER Start with active surveillance by monitoring PSA/DRE/Biopsies. Radiation - Has a lot of GIT complications and may lead to erectile Dysfunction. Brachytherapy is the new treatment. Radical Prostatectomy - May lead to neruovascular damage causing Erectile Dysfunction and damage to urethra my lead to incontinence. After treatment continue to monitor PSA to look for Metastasis or resurgency of cancer. TREATMENT OF METASTASIS OF PROSTATE CANCER Castration - Orchiectomy (Gold Standard), Leuprolide/Ghrelin (GnRH) but these have a temporary increase in androgens, and Anti-Androgens (Flutamide). Castration Resistant Prostate Cancer (CRPC) are tumors that are still growing despite castration. Then use chemotherapy (Doxitexal, Mitoxantrone, Dosatinib)
Просмотров: 35750 the study spot
Dr. Concepcion on The Use of Eligard in Prostate Cancer Treatment
 
02:28
Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.
Просмотров: 810 OncLiveTV
Mal's story - 11 years prostate cancer, 5 years metastatic
 
04:58
11 years prostate cancer, 5 years metastatic, no symptoms, another health problem ... but Alison's beautiful words to help them deal with life's problems star in this short video. Many thanks to Mal and Alison who us a glimpse of their private life in order to help others. Many thanks to my 12 year old grandson Matthew McKewin. Matthew gave up the first fortnight of his summer holidays to learn to use the video camera, then recorded all the location shots in this video. Grandfather is very proud of him.
Просмотров: 1157 JimJimJimJim
Link Discovered Between Hormone Therapy for Prostate Cancer and Depression
 
00:51
A new study suggests older men who receive testosterone-suppressing therapy for prostate cancer may be at increased risk of developing depression. The findings are based on a large study of 78,000 U.S. men treated for earlier-stage prostate cancer. Researchers found that among those given hormone-suppressing therapy, 7 percent developed clinical depression in the next few years. 5 percent of men who did not have the treatment also developed depression. The findings do not prove that hormone therapy is to blame. However, senior researcher Dr. Paul Nguyen of Brigham and Women's Hospital in Boston says they do offer "pretty strong evidence" that might be the case. Nguyen said his team accounted for some other factors that could affect depression risk -- including the severity of a man's cancer, his age and education. And there was still a connection between hormone therapy and depression. Also, the longer the men were on hormone therapy, the higher the risk of depression. http://www.upi.com/Health_News/2016/04/11/Hormone-therapy-for-prostate-cancer-tied-to-depression/9031460418049/ http://www.wochit.com This video was produced by YT Wochit News using http://wochit.com
Просмотров: 299 Wochit News
Early Castration Resistance depends on Lupron Regimen .mp4
 
05:33
Early Castration Resistance depends on Lupron Regimen .mp4
Просмотров: 736 DrBarken
Firmagon V Lupron + PCa Remissions
 
04:45
Purchase a transcript here: https://rivanna-health-publications.myshopify.com
Просмотров: 1171 ProstateForum
Is Abiraterone Acetate Useful for Prostate Cancer?
 
02:30
Some reports suggest that Abiraterone Acetate may be a new treatment for prostate cancer. Find out the latest information.
Просмотров: 2919 Gerald Chodak MD
Lupron side effects
 
09:28
6 days after first Lupron injection. Side effects and vitamins I am currently taking.
Просмотров: 12551 Alexandria Marchak
Urologist says female hormone injections pose risks for those with prostate cancer
 
02:06
Every year, 50,000 American men have a recurrence of prostate cancer because their first treatment failed.
Просмотров: 438 WPLG Local 10
How does leuprolide work
 
02:01
How does leuprolide work - Find out more explanation for : 'How does leuprolide work' only from this channel. Information Source: google
Просмотров: 19 moibrad7a
Hormone Therapy and Prostate Cancer | Dana-Farber Cancer Institute
 
02:15
Mark Pomerantz, MD, of Dana-Farber's Lank Center for Genitourinary Oncology, discusses how hormone therapy is used to treat prostate cancer.
Просмотров: 187 Dana-Farber Cancer Institute
Side effects of Lupron
 
09:58
Просмотров: 9008 Karina Diaz
Abiraterone Acetate Plus Prednisone in Prostate Cancer
 
05:33
With Peter De Porre, MD
Просмотров: 850 Cancer Therapy Advisor
Lupron side effects, updates and questions
 
06:11
Просмотров: 6674 Megan Ross
How do GnRH analogues work? Zoladex, Prostap and other GnRH analogues
 
05:22
A simple explanation of how GnRH analogues like goserelin (Zoladex) and Leuprorelin (Prostap) work to induce a medical menopause or medical castration to treat conditions like endometriosis and prostate cancer. This includes a basic explanation of the hypothalamic-pituitary-gonadal axis in men and women. I love creating resources to help medical students with their studies. Why not have a look at some of the other resources available: Website: www.zerotofinals.com Notes: www.zerotofinals.com/learn Multiple Choice Questions: www.zerotofinals.com/test Instagram: www.instagram.com/zerotofinals/ Book: www.zerotofinals.com/themedicinemanual Facebook: www.facebook.com/zerotofinals Twitter: https://twitter.com/zerotofinals
Просмотров: 2342 Zero To Finals
Dr. Slovin Discusses a Study Comparing Cardiovascular Events With Degarelix or Leuprolide
 
02:42
Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.
Просмотров: 139 OncLiveTV
Optimizing Androgen Deprivation Therapy in High-Risk Prostate Cancer
 
07:25
In this segment, panelists discuss the optimization of treatments administered for patients with high-risk prostate cancer following progression on definitive therapies, such as radical prostatectomy. For more from this discussion, visit http://www.onclive.com/peer-exchange/prostate-guidelines
Просмотров: 618 OncLiveTV
Dr. Mary-Ellen Taplin on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate
 
01:41
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, discusses a randomized phase II trial that provided abiraterone acetate (Zytiga) in combination with the hormonal therapy leuprolide acetate before prostatectomy for men with localized high-risk prostate cancer (LHRPC).
Просмотров: 634 OncLiveTV
Treating High-Risk Localized Prostate Cancer
 
09:46
Multiple treatment options exist for patients with high-risk localized or advanced prostate cancer, making the optimal treatment decision difficult, since it will likely require multiple modalities. In this segment, panelists explore the intricacies of treating patients in this setting. For more from this discussion, visit http://www.onclive.com/peer-exchange/prostate-guidelines
Просмотров: 3021 OncLiveTV
Leuprolide Acetate Injection (Lupron)
 
01:14
Leuprolide Acetate (Lupron) is related to a naturally occurring hormone called gonadotropin releasing hormone (GnRH). Leuprolide Acetate has also been used to treat endometriosis, uterine fibroids, early puberty, and as part of the process to stimulate multiple eggs for assisted reproductive technologies. The strength of Leuprolide Acetate is 1mg/0.2ml. Leuprolide Acetate is administered as a subcutaneous injection using insulin syringes. Insulin syringes are used because the measurement on the syringe is in units (i.e.: 10 units is equivalent to 0.1ml/cc). For the role it plays in assisted reproductive technologies, Leuprolide Acetate is used to reduce the amount of estrogen and testosterone in the body. This decrease in estrogen production will prevent ovulation and stop menstrual periods. For questions regarding medication administration or to speak to our nurse or pharmacist, please call 877-334-1610.
Просмотров: 75166 Village Pharmacy
Dr. Mary-Ellen Taplin on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer
 
01:49
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, explains the rationale behind the recent study examining the neoadjuvant administration of abiraterone acetate (Zytiga) in combination with the LHRH analog leuprolide acetate, for patients with localized high-risk prostate cancer. To read more, visit http://www.onclive.com/onclive-tv/Dr-Taplin-on-Neoadjuvant-ADT-Plus-Hormonal-Therapy
Просмотров: 296 OncLiveTV
1  Leuprolide Acetate Injection Procedure
 
03:00
Просмотров: 8877 Matt Biagiotti
Dr. Burgess on the Synergy Between Abiraterone and ADT in Prostate Cancer
 
01:11
Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, discusses the synergy between abiraterone acetate (Zytiga) and androgen deprivation therapy (ADT) in prostate cancer.
Просмотров: 53 OncLiveTV
Side Effects of Lupron Depot  - Crazy Lady Symptoms
 
10:16
Lupron Depot Side effects as I prep for another IVF FET coming December. Insta: instagram.com/liv4todayvlog Facebook: https://www.facebook.com/liv4todayvlog/ blog: femmeinfertile.blogspot.com Music: http://www.bensound.com/royalty-free-music
Просмотров: 4344 Liv 4 Today
TERRAIN: Enzalutamide versus bicalutamide for metastatic prostate cancer
 
01:30
Neal Shore, MD, FACS, from Atlantic Urology Clinics, Myrtle Beach, SC, discusses the results of the randomized, double-blind, phase 2 TERRAIN trial, which compared enzalutamide, a novel androgen receptor signalling inhibitor, with bicalutamide, a non-steroidal anti-androgen, for the treatment of men with metastatic castrate-resistant prostate cancer. Recorded at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting,
Просмотров: 384 Cancer ASEA
Lupron Side Effects
 
02:50
Insomnia Dry skin Night sweats Hot flashes
Просмотров: 66 ButtaflyPoet
Dr. Shore on Degarelix Versus LHRH Agonists in Prostate Cancer
 
01:39
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, discusses an analysis of degarelix and luteinising hormone-releasing hormone (LHRH) agonists in prostate cancer. For more information on prostate cancer: http://www.onclive.com/specialty/prostate-cancer
Просмотров: 341 OncLiveTV
Dr. Charles Ryan Discusses Neoadjuvant Abiraterone Acetate
 
01:22
Charles J. Ryan, MD, medical oncologist, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a recent clinical trial presented at the 2012 ASCO Annual Meeting that investigated the neoadjuvant administration of abiraterone acetate (Zytiga) in combination with leuprolide acetate for patients with localized high-risk prostate cancer. Read more, at http://www.onclive.com/onclive-tv/Dr-Ryan-Discusses-Neoadjuvant-Abiraterone-Acetate
Просмотров: 241 OncLiveTV
NICE decision to reject prostate cancer drug Abiraterone
 
02:46
Prostate Action CEO Emma Malcolm discusses the decision from NICE to reject Abiraterone for use by the NHS, a drug used to treat advanced prostate cancer.
Просмотров: 605 ProstateAction
LUPRON DAY 4.My Thoughts on Leuprolide so far
 
01:24
Thanks For Watching !!!
Просмотров: 183 Nickeyibelieve30